NASDAQ:RNTX Rein Therapeutics (RNTX) Stock Price, News & Analysis $1.11 0.00 (0.00%) As of 08/8/2025 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Rein Therapeutics Stock (NASDAQ:RNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rein Therapeutics alerts:Sign Up Key Stats Today's Range$1.06▼$1.1450-Day Range$1.11▼$2.0252-Week Range$1.04▼$4.40Volume34,950 shsAverage Volume57,282 shsMarket Capitalization$25.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. Read More Receive RNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rein Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RNTX Stock News HeadlinesXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationAugust 7 at 2:14 AM | finance.yahoo.comRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingJuly 30, 2025 | finance.yahoo.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation. | Paradigm Press (Ad)RNTX - Rein Therapeutics Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMRein Therapeutics Announces Adjournment of Annual Meeting of StockholdersJune 24, 2025 | prnewswire.comUS FDA puts on hold Rein Therapeutics' lung disease drug trialJune 12, 2025 | reuters.comRNTX Rein Therapeutics Inc.June 1, 2025 | seekingalpha.comRein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | finanznachrichten.deSee More Headlines RNTX Stock Analysis - Frequently Asked Questions How have RNTX shares performed this year? Rein Therapeutics' stock was trading at $2.05 at the start of the year. Since then, RNTX shares have decreased by 45.9% and is now trading at $1.11. How were Rein Therapeutics' earnings last quarter? Rein Therapeutics Inc. (NASDAQ:RNTX) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. Who are Rein Therapeutics' major shareholders? Rein Therapeutics' top institutional shareholders include University of Texas Texas AM Investment Management Co. (2.31%), Sigma Planning Corp (1.20%), Geode Capital Management LLC (1.06%) and Chicago Partners Investment Group LLC (0.19%). How do I buy shares of Rein Therapeutics? Shares of RNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2025Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNTX CIK1420565 WebN/A Phone(737) 802-1989FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-86.07% Return on Assets-31.11% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.45 per share Price / Cash Flow2.48 Book Value$0.43 per share Price / Book2.58Miscellaneous Outstanding Shares23,050,000Free Float21,871,000Market Cap$25.59 million OptionableN/A Beta1.31 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RNTX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.